Updated: Dec 18, 2020
Shenyang Daily 16-04-2020
On the afternoon of April 14, at the press conference of the Joint Prevention and Control Mechanism of the State Council, Sun Yanrong, Deputy Director of the Biological Center of the Ministry of Science and Technology of PRC, said in response to a question raised by a reporter from the CNR (China National Radio) China Media Group that the experience and reference provided by China for global epidemic prevention and control are mainly reflected in the publication and exchange of academic papers on clinical research of drugs against COVID-19 in international journals, the continuous and frequent exchanges and academic discussions by Chinese scientific research teams with 140 countries and regions around the world, and recommendations of research results of both self-developed drugs and drugs under international cooperation.
When talking about the R&D of anti-epidemic drugs in China, Sun Yanrong specifically mentioned Chinese Primary Drug Carrimycin, saying that the country is actively promoting the in-depth clinical research of Chinese self-developed drugs such as Carrimycin. It indicates that Chinese primary drug Carrimycin is the first domestic biosynthetic drug entering the “China’s plan”, following the “Three Drugs and Three Prescriptions” proposed by TCM.
On March 26, Xu Nanping, the Vice Minister of the Ministry of Science and Technology of PRC, announced at a press conference of the State Council that clinical trials had proven that Carrimycin is an effective drug for the treatment of COVID-19, and in particular, it plays a positive role in preventing patients with mild symptoms from transforming into critical patients.
The fact Carrimycin was mentioned at the two press conferences with an interval less than 20 days indicates that the clinical research of Carrimycin has made significant progress, and it is just around the corner to enter the phase of full clinical application.
Carrimycin is the world’s first Chinese Class 1 new drug produced by using synthetic biology technology. It is jointly developed by Shenyang Tonglian Group Co., Ltd. and the Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, and has completely independent Chinese intellectual property.
Reporter Chen Hongbo